Fig. 1: Patient disposition.
From: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
CAPOX, oxaliplatin and capecitabine; EC, encorafenib and cetuximab; mFOLFOX6, oxaliplatin, leucovorin and 5-FU; FOLFOXIRI, irinotecan, oxaliplatin, leucovorin and 5-FU; mCRC, metastatic colorectal cancer; SOC, standard of care. aOne participant who was randomized to the EC+mFOLFOX6 arm (but never treated) was inadvertently entered as withdrawal by subject on the screening case report form page. bFollowing closure of the EC arm, randomization was 1:1 to the EC+mFOLFOX6 and SOC arms.
